Prior to FDA clearance of the NxStage System One, home hemodialysis (HHD) in the United States had experienced significant decline. According to the 2011 United States Renal Data System's Annual Data Report, which reflects data through 2009, the number of patients performing home hemodialysis treatments in the US had dropped from approximately 3,000 patients in 1990 to 1,761 patients in 2002. The NxStage System One has helped ignite a new wave of HHD therapy adoption, more than doubling the number of patients performing hemodialysis in their homes in its first 5 years on the market.
NxStage's home hemodialysis experience to date with the System One includes:
- More than 4.5 million home hemodialysis treatments delivered
- More than 5000 patients currently using the NxStage System One for home hemodialysis therapy.
- Patients from the initial NxStage IDE study now active on therapy for more than 8 years